GPX4 and cancer: Interestingly, silencing of LDHB did not further sensitize PANC-1 and MSTO-211H cancer cells to FIN56 treatment compared with control silencing (Fig. 4e and Supplementary Fig. 4m, respectively), revealing that the anti-ferroptotic function of LDHB overlaps with the functions that are inhibited by FIN56, e.g., the GPX4- and CoQ-dependent pathways44.